

Supporting information for

Natural acetogenins, chatenaitrienins-1, -2, -3 and -4 - mito-chondrial potential uncouplers and autophagy inducers - promising anticancer agents

Lilya U. Dzhemileva *, Regina A. Tuktarova, Usein M. Dzhemilev,
and Vladimir A. D'yakonov *

*N.D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences,
Leninsky Prospect 47, Moscow 119991, Russia;
regina-tuktarova@yandex.ru (R.A.T.); dzhemilev@anrb.ru (U.M.D.)*


* Correspondence: dzhemileval@ioc.ac.ru (L.U.D.);
dyakonovva@ioc.ac.ru (V.A.D.)

Table of contents

- | | |
|--|-----|
| 1. ^1H and ^{13}C NMR Spectra of the compounds 25–27, 29–31, 33–35, 37–39 | S3 |
| 2. Figures for spectrum of the compounds 25–27, 29–31, 33–35, 37–39 | S10 |


¹H and ¹³C NMR Spectra of the compounds 25–27, 29–31, 33–35, 37–39

2-[(9Z,13Z,17Z)-Triaconta-9,13,17-trien-1-yloxy]tetrahydro-2H-pyran (25)




Pale yellow oily liquid; ¹H NMR (500 MHz, CDCl₃): 5.44–5.35 (m, 6H), 4.59 (m, 1H), 3.88 (m, 1H), 3.75 (m, 1H), 3.50 (m, 1H), 3.40 (m, 1H), 2.12–2.01 (m, 12H), 1.86 (m, 1H), 1.73 (m, 1H), 1.63–1.52 (m, 6H), 1.40–1.25 (m, 30H), 0.89 (t, *J* = 6.5 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃): 130.4, 130.3, 129.6 (signals of 2C), 129.1 (signals of 2C), 98.8, 67.7, 62.3, 31.9, 30.8, 29.8–29.3 (signals of 13C), 27.5 (signals of 2C), 27.4 (signals of 2C), 27.3 (signals of 2C), 26.3, 25.5, 22.7, 19.7, 14.1; IR (film): 3008, 2956, 2924, 2853, 1619, 1465, 1352, 1273, 1201, 1137, 1120, 1079, 1034, 970, 908, 869, 815, 722 cm⁻¹; Analysis calculated for C₃₅H₆₄O₂: C, 81.33; H, 12.48. Found: C, 81.21; H, 12.45. MALDI TOF: m/z 539.509 ([M+Na]⁺, calcd 539.491).

2-[(11Z,15Z,19Z)-Dotriaconta-11,15,19-trien-1-yloxy]tetrahydro-2H-pyran (26)




Pale yellow oily liquid; ¹H NMR (500 MHz, CDCl₃): 5.44–5.35 (m, 6H), 4.59 (m, 1H), 3.88 (m, 1H), 3.74 (m, 1H), 3.51 (m, 1H), 3.39 (m, 1H), 2.13–2.00 (m, 12H), 1.85 (m, 1H), 1.72 (m, 1H), 1.63–1.52 (m, 6H), 1.40–1.25 (m, 34H), 0.89 (t, *J* = 6.5 Hz, 3H); ¹³C NMR (125 MHz, CDCl₃): 130.4 (signals of 2C), 129.6 (signals of 2C), 129.1 (signals of 2C), 98.8, 67.7, 62.3, 31.9, 30.8, 29.8–29.4 (signals of 15C), 27.5 (signals of 2C), 27.4 (signals of 2C), 27.3 (signals of 2C), 26.3, 25.5, 22.7, 19.7, 14.1; IR (film): 3007, 2925, 2854, 1621, 1464, 1377, 1353, 1271, 1136, 1122, 1035, 970, 907, 869, 815, 721 cm⁻¹; Analysis calculated for C₃₇H₆₈O₂: C, 81.55; H, 12.58. Found: C, 81.38; H, 12.55. MALDI TOF: m/z 567.479 ([M+Na]⁺, calcd 567.512), 583.503 ([M+K]⁺, calcd 583.486).

2-[(13Z,17Z,21Z)-Dotriaconta-13,17,21-trien-1-yloxy]tetrahydro-2H-pyran (27)




Pale yellow oily liquid; ^1H NMR (500 MHz, CDCl_3): 5.44–5.34 (m, 6H), 4.59 (m, 1H), 3.88 (m, 1H), 3.76 (m, 1H), 3.52 (m, 1H), 3.39 (m, 1H), 2.13–1.98 (m, 12H), 1.86 (m, 1H), 1.73 (m, 1H), 1.64–1.52 (m, 6H), 1.40–1.23 (m, 34H), 0.91 (t, $J = 6.5$ Hz, 3H); ^{13}C NMR (125 MHz, CDCl_3): 130.4 (signals of 2C), 129.6 (signals of 2C), 129.1 (signals of 2C), 98.8, 67.7, 62.3, 31.9, 30.8, 29.8–29.3 (signals of 15C), 27.5 (signals of 2C), 27.4 (signals of 2C), 27.3 (signals of 2C), 26.3, 25.5, 22.7, 19.7, 14.1; IR (film): 3007, 2925, 2854, 1621, 1464, 1377, 1353, 1271, 1136, 1122, 1035, 970, 907, 869, 815, 721 cm^{-1} ; Analysis calculated for $\text{C}_{37}\text{H}_{68}\text{O}_2$: C, 81.55; H, 12.58. Found: C, 81.37; H, 12.56. MALDI TOF: m/z 567.466 ($[\text{M}+\text{Na}]^+$, calcd 567.512).

(9Z,13Z,17Z)-Triaconta-9,13,17-trienoic acid (29)




Colorless oil; ^1H NMR (400 MHz, CDCl_3): 5.45–5.35 (m, 6H), 2.37 (t, $J = 7.6$ Hz, 2H), 2.13–2.02 (m, 12H), 1.65 (m, 2H), 1.40–1.25 (m, 28H), 0.91 (t, $J = 6.4$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3): 179.9, 130.4, 130.3, 129.7, 129.6, 129.2, 129.1, 34.0, 31.9, 29.8–29.0 (signals of 12C), 27.4 (signals of 2C), 27.3 (signals of 2C), 27.2 (signals of 2C), 24.7, 22.7, 14.1; IR (film): 3006, 2924, 2854, 1711, 1464, 1378, 1285, 1248, 1087, 966, 940, 723 cm^{-1} ; Analysis calculated for $\text{C}_{30}\text{H}_{54}\text{O}_2$: C, 80.65; H, 12.18. Found: C, 80.49; H, 12.16. MALDI TOF: m/z 469.435 ($[\text{M}+\text{Na}]^+$, calcd 469.402), 485.408 ($[\text{M}+\text{K}]^+$, calcd 485.376).

(11Z,15Z,19Z)-Triaconta-11,15,19-trienoic acid (30)




Colorless oil; ^1H NMR (400 MHz, CDCl_3): 5.45–5.35 (m, 6H), 2.37 (t, $J = 7.2$ Hz, 2H), 2.13–2.02 (m, 12H), 1.65 (m, 2H), 1.40–1.26 (m, 32H), 0.91 (t, $J = 6.4$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3): 180.2, 130.4, 130.3, 129.6 (signals of 2C), 129.1 (signals of 2C), 34.1, 31.9, 29.7–29.1 (signals of 14C), 27.5 (signals of 2C), 27.4 (signals of 2C), 27.3 (signals of 2C), 24.7, 22.7, 14.1; IR (film): 3006, 2925, 2854, 1712, 1465, 1377, 1285, 1243, 1086, 963, 941, 722 cm^{-1} ; Analysis calculated for $\text{C}_{32}\text{H}_{58}\text{O}_2$: C, 80.95; H, 12.31. Found: C, 80.87; H, 12.29. MALDI TOF: m/z 497.512 ($[\text{M}+\text{Na}]^+$, calcd 497.433).

(13Z,17Z,21Z)-Triaconta-13,17,21-trienoic acid (31)




Colorless oil; ^1H NMR (400 MHz, CDCl_3): 5.46–5.35 (m, 6H), 2.37 (t, $J = 7.2$ Hz, 2H), 2.13–2.02 (m, 12H), 1.66 (m, 2H), 1.40–1.26 (m, 32H), 0.91 (t, $J = 6.4$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3): 180.2, 130.4 (signals of 2C), 129.6 (signals of 2C), 129.1 (signals of 2C), 34.1, 31.9, 29.8–29.1 (signals of 14C), 27.5 (signals of 2C), 27.4 (signals of 2C), 27.3 (signals of 2C), 24.7, 22.7, 14.1; IR (film): 3006, 2924, 2854, 1713, 1463, 1377, 1285, 1242, 1063, 965, 941, 721 cm^{-1} ; Analysis calculated for $\text{C}_{32}\text{H}_{58}\text{O}_2$: C, 80.95; H, 12.31. Found: C, 80.88; H, 12.29. MALDI TOF: m/z 497.504 ($[\text{M}+\text{Na}]^+$, calcd 497.433), 513.489 ($[\text{M}+\text{K}]^+$, calcd 513.407).

(5S)-4-Hydroxy-5-methyl-3-[(9Z,13Z,17Z)-triaconta-9,13,17-trien-1-yl]furan-2(5H)-one (33)




Colourless solid; $[\alpha]_D^{19} = -3.8$ (c 0.74, CHCl_3); ^1H NMR (400 MHz, CDCl_3): 5.43–5.36 (m, 6H), 4.85 (q, $J = 6.8$ Hz, 1H), 2.22 (t, $J = 7.2$ Hz, 2H), 2.12–2.00 (m, 12H), 1.52 (d, $J = 6.8$ Hz, 3H), 1.49 (m, 2H), 1.38–1.25 (m, 30H), 0.90 (t, $J = 6.8$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3): 177.8, 177.6, 130.4, 130.3, 129.6 (signals of 2C), 129.1 (signals of 2C), 100.9, 75.4, 31.9, 29.7–29.4 (signals of 13C), 28.1, 27.4 (signals of 2C), 27.3 (signals of 4C), 22.7, 21.1, 17.8, 14.1; IR (film): 3005, 2924, 2854, 1722, 1652, 1543, 1456, 1399, 1375, 1342, 1283, 1076, 968, 722 cm^{-1} ; Analysis calculated for $\text{C}_{35}\text{H}_{60}\text{O}_3$: C, 79.49; H, 11.44. Found: C, 79.39; H, 11.41. MALDI TOF: m/z 551.524 ($[\text{M}+\text{Na}]^+$, calcd 551.444), 567.502 ($[\text{M}+\text{K}]^+$, calcd 567.418).

(5S)-4-Hydroxy-5-methyl-3-[(11Z,15Z,19Z)-dotriaconta-11,15,19-trien-1-yl]furan-2(5H)-one (34)




Colourless solid; $[\alpha]_D^{22} = -5.2$ (*c* 0.63, CHCl₃); ¹H NMR (400 MHz, CDCl₃): 5.43–5.36 (m, 6H), 4.85 (q, *J* = 6.8 Hz, 1H), 2.22 (t, *J* = 7.2 Hz, 2H), 2.13–2.00 (m, 12H), 1.52 (d, *J* = 6.8 Hz, 3H), 1.49 (m, 2H), 1.38–1.24 (m, 34H), 0.90 (t, *J* = 6.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): 177.8, 177.6, 130.4, 130.3, 129.6 (signals of 2C), 129.1 (signals of 2C), 100.9, 75.4, 31.9, 29.7–29.3 (signals of 15C), 28.1, 27.5 (signals of 2C), 27.4 (signals of 2C), 27.3 (signals of 2C), 22.7, 21.1, 17.8, 14.1; IR (film): 3005, 2924, 2853, 1732, 1653, 1558, 1542, 1457, 1399, 1076, 968, 722 cm⁻¹; Analysis calculated for C₃₇H₆₄O₃: C, 79.80; H, 11.58. Found: C, 79.69; H, 11.55. MALDI TOF: m/z 579.501 ([M+Na]⁺, calcd 579.475).

(5*S*)-4-Hydroxy-5-methyl-3-[(13*Z*,17*Z*,21*Z*)-dotriaconta-13,17,21-trien-1-yl]furan-2(5*H*)-one (35)




Colourless solid; $[\alpha]_D^{21} = -1.5$ (*c* 0.85, CHCl₃); ¹H NMR (400 MHz, CDCl₃): 5.43–5.35 (m, 6H), 4.82 (q, *J* = 6.4 Hz, 1H), 2.21 (t, *J* = 7.6 Hz, 2H), 2.13–2.00 (m, 12H), 1.50 (d, *J* = 6.8 Hz, 3H), 1.49 (m, 2H), 1.38–1.24 (m, 34H), 0.89 (t, *J* = 6.4 Hz, 3H); ¹³C NMR (100 MHz, CDCl₃): 177.7, 177.5, 130.4 (signals of 2C), 129.6 (signals of 2C), 129.1 (signals of 2C), 101.0, 75.0, 31.9, 29.7–29.4 (signals of 15C), 28.1, 27.5 (signals of 2C), 27.4 (signals of 2C), 27.3 (signals of 2C), 22.7, 21.1, 17.9, 14.1; IR (film): 3005, 2924, 2854, 1752, 1649, 1459, 1400, 1377, 1076, 968, 722 cm⁻¹; Analysis calculated for C₃₇H₆₄O₃: C, 79.80; H, 11.58. Found: C, 79.67; H, 11.56. MALDI TOF: m/z 579.426 ([M+Na]⁺, calcd 579.475), 579.376 ([M+Na]⁺, calcd 595.449).

(2*S*)-2-Methyl-5-oxo-4-[(9*Z*,13*Z*,17*Z*)-triaconta-9,13,17-trien-1-yl]-2,5-dihydrofuran-3-yl trifluoromethanesulfonate (37)




Pale yellow oil; $[\alpha]_D^{19} = +30.9$ (c 0.73, CHCl_3); ^1H NMR (500 MHz, CDCl_3): 5.44–5.37 (m, 6H), 5.13 (q, $J = 6.4$ Hz, 1H), 2.33 (m, 2H), 2.13–2.00 (m, 12H), 1.60 (m, 2H), 1.56 (d, $J = 6.4$ Hz, 3H), 1.37–1.26 (m, 30H), 0.89 (t, $J = 6.4$ Hz, 3H); ^{13}C NMR (125 MHz, CDCl_3): 169.0, 163.4, 130.4, 130.3, 129.6 (signals of 2C), 129.1 (signals of 2C), 121.9, 118.4 ($J = 319$ Hz), 74.4, 31.9, 29.7–29.1 (signals of 13C), 27.5, 27.4 (signals of 3C), 27.3, 27.2, 26.7, 22.7 (signals of 2C), 17.7, 14.1; IR (film): 3006, 2925, 2854, 1782, 1699, 1436, 1379, 1341, 1222, 1138, 1104, 1068, 944, 808, 764, 723, 605 cm^{-1} ; Analysis calculated for $\text{C}_{36}\text{H}_{59}\text{F}_3\text{O}_5\text{S}$: C, 65.42; H, 9.00. Found: C, 65.35; H, 8.98. MALDI TOF: m/z 683.503 ($[\text{M}+\text{Na}]^+$, calcd 683.404).

(2S)-2-Methyl-5-oxo-4-[(11Z,15Z,19Z)-triaconta-11,15,19-trien-1-yl]-2,5-dihydrofuran-3-yl trifluoromethanesulfonate (38)




Pale yellow oil; $[\alpha]_D^{22} = +17.4$ (c 0.84, CHCl_3); ^1H NMR (400 MHz, CDCl_3): 5.44–5.37 (m, 6H), 5.13 (q, $J = 6.4$ Hz, 1H), 2.33 (m, 2H), 2.13–2.00 (m, 12H), 1.60 (m, 2H), 1.56 (d, $J = 6.4$ Hz, 3H), 1.37–1.25 (m, 34H), 0.90 (t, $J = 6.8$ Hz, 3H); ^{13}C NMR (100 MHz, CDCl_3): 169.1, 163.4, 130.4 (signals of 2C), 129.6 (signals of 2C), 129.1 (signals of 2C), 121.9, 118.4 ($J = 319$ Hz), 74.4, 31.9, 29.7–29.1 (signals of 15C), 27.5 (signals of 2C), 27.4 (signals of 2C), 27.3 (signals of 2C), 26.7, 22.7 (signals of 2C), 17.7, 14.1; IR (film): 3006, 2925, 2854, 1782, 1699, 1436, 1378, 1340, 1222, 1139, 1103, 1068, 940, 808, 764, 723, 605 cm^{-1} ; Analysis calculated for $\text{C}_{38}\text{H}_{63}\text{F}_3\text{O}_5\text{S}$: C, 66.25; H, 9.22. Found: C, 66.13; H, 9.19. MALDI TOF: m/z 711.513 ($[\text{M}+\text{Na}]^+$, calcd 711.425), 727.417 ($[\text{M}+\text{Na}]^+$, calcd 727.399).

(2S)-2-Methyl-5-oxo-4-[(13Z,17Z,21Z)-triaconta-13,17,21-trien-1-yl]-2,5-dihydrofuran-3-yl trifluoromethanesulfonate (39)




Pale yellow oil; $[\alpha]_D^{19} = +22$. (c 0.85, CHCl_3); ^1H NMR (500 MHz, CDCl_3): 5.45–5.35 (m, 6H), 5.13 (q, $J = 6.4$ Hz, 1H), 2.33 (m, 2H), 2.13–2.01 (m, 12H), 1.61 (m, 2H), 1.56 (d, $J = 6.8$ Hz, 3H), 1.38–1.25 (m, 34H), 0.89 (t, $J = 6.8$ Hz, 3H); ^{13}C NMR (125 MHz, CDCl_3): 169.0, 163.4, 130.4 (signals of 2C), 129.6 (signals of 2C), 129.1 (signals of 2C), 121.9, 118.4 ($J = 319$ Hz), 74.4, 31.9, 29.8–29.1 (signals of 15C), 27.5 (signals of 2C), 27.4 (signals of 2C), 27.3 (signals of 2C), 26.7, 22.7 (signals of 2C), 17.7, 14.1; IR (film): 3006, 2926, 2854, 1782, 1699, 1436, 1341, 1323, 1223, 1138, 1102, 1068, 939, 808, 764, 723, 605 cm^{-1} ; Analysis calculated for $\text{C}_{38}\text{H}_{63}\text{F}_3\text{O}_5\text{S}$: C, 66.25; H, 9.22. Found: C, 66.11; H, 9.20. MALDI TOF: m/z 711.282 ($[\text{M}+\text{Na}]^+$, calcd 711.425).

(5S)-5-Methyl-3-[(9Z,13Z,17Z)-triaconta-9,13,17-trien-1-yl]furan-2(5H)-one (2)
(Chatenaytrienin-2)



Colourless waxy solid; $[\alpha]_D^{21} = +12.2$ (c 0.76, CHCl_3); ^1H NMR (500 MHz, CDCl_3): 6.99 (d, $^3J = 1.2$ Hz, 1H), 5.45–5.34 (m, 6H), 5.00 (qd, $^3J = 6.8$, $^3J = 1.6$ Hz, 1H), 2.28 (t, $J = 7.6$ Hz, 2H), 2.13–2.00 (m, 12H), 1.57 (m, 2H), 1.42 (d, $J = 6.8$ Hz, 3H), 1.38–1.26 (m, 30H), 0.89 (t, $J = 6.8$ Hz, 3H); ^{13}C NMR (125 MHz, CDCl_3): 173.9, 148.8, 134.3, 130.4, 130.3, 129.6 (signals of 2C), 129.2, 129.1, 77.3, 31.9, 29.8–29.2 (signals of 13C), 27.5, 27.4 (signals of 4C), 27.3 (signals of 2C), 25.2, 22.7, 19.2, 14.1; IR (film): 3005, 2925, 2853, 1759, 1616, 1456, 1374, 1318, 1198, 1072, 1027, 843, 742, 699 cm^{-1} ; Analysis calculated for $\text{C}_{35}\text{H}_{60}\text{O}_2$: C, 81.97; H, 11.79. Found: C, 81.83; H, 11.75. MALDI TOF: m/z 535.481 ($[\text{M}+\text{Na}]^+$, calcd 535.449), 551.529 ($[\text{M}+\text{K}]^+$, calcd 551.423). HRMS (ESI-TOF): calcd for $\text{C}_{35}\text{H}_{60}\text{O}_2\text{Na}$ $[\text{M}+\text{Na}]^+$ 535.4491, found 535.4437.


(5S)-5-Methyl-3-[(11Z,15Z,19Z)-triaconta-11,15,19-trien-1-yl]furan-2(5H)-one (3)
(Chatenaytrienin-3)



Colourless waxy solid; $[\alpha]_D^{21} = +9.1$ (c 0.73, CHCl_3); ^1H NMR (500 MHz, CDCl_3): 6.99 (d, $^3J = 1.2$ Hz, 1H), 5.45–5.34 (m, 6H), 5.00 (qd, $^3J = 6.8$, $^3J = 1.6$ Hz, 1H), 2.28 (t, $J = 7.8$ Hz, 2H), 2.13–2.00 (m, 12H), 1.56 (m, 2H), 1.42 (d, $J = 6.4$ Hz, 3H), 1.38–1.26 (m, 34H), 0.90 (t, $J =$

6.8 Hz, 3H); ^{13}C NMR (125 MHz, CDCl_3): 173.9, 148.8, 134.3, 130.4 (signals of 2C), 129.6 (signals of 2C), 129.1 (signals of 2C), 77.3, 31.9, 29.8–29.2 (signals of 15C), 27.5 (signals of 2C), 27.4 (signals of 2C), 27.3 (signals of 3C), 25.2, 22.7, 19.2, 14.1; IR (film): 3006, 2924, 2853, 1760, 1618, 1464, 1374, 1318, 1180, 1118, 1077, 1027, 857, 798, 722 cm^{-1} ; Analysis calculated for $\text{C}_{37}\text{H}_{64}\text{O}_2$: C, 82.16; H, 11.93. Found: C, 82.01; H, 11.93. MALDI TOF: m/z 563.453 ($[\text{M}+\text{Na}]^+$, calcd 563.480), 579.509 ($[\text{M}+\text{K}]^+$, calcd 579.454). HRMS (ESI-TOF): calcd for $\text{C}_{37}\text{H}_{64}\text{O}_2\text{Na}$ $[\text{M}+\text{Na}]^+$ 563.4804, found 563.4626.

**(5S)-5-Methyl-3-[(13Z,17Z,21Z)-triaconta-13,17,21-trien-1-yl]furan-2(5H)-one (4)
(Chatenaytrienin-4)**



Colourless waxy solid; $[\alpha]_D^{17} = +29.0$ (c 0.74, CHCl_3); ^1H NMR (500 MHz, CDCl_3): 7.00 (d, $^3J = 1.2$ Hz, 1H), 5.45–5.34 (m, 6H), 5.01 (qd, $^3J = 6.8$, $^3J = 1.6$ Hz, 1H), 2.28 (t, $J = 7.6$ Hz, 2H), 2.13–1.99 (m, 12H), 1.55 (m, 2H), 1.42 (d, $J = 6.4$ Hz, 3H), 1.38–1.26 (m, 34H), 0.90 (t, $J = 6.5$ Hz, 3H); ^{13}C NMR (125 MHz, CDCl_3): 173.9, 148.8, 134.4, 130.4 (signals of 2C), 129.6 (signals of 2C), 129.1 (signals of 2C), 77.4, 31.9, 29.8–29.2 (signals of 15C), 27.5 (signals of 2C), 27.4 (signals of 2C), 27.3 (signals of 3C), 25.2, 22.7, 19.2, 14.1; IR (film): 3006, 2924, 2853, 1759, 1619, 1464, 1376, 1318, 1261, 1195, 1076, 1028, 857, 799, 723 cm^{-1} ; Analysis calculated for $\text{C}_{37}\text{H}_{64}\text{O}_2$: C, 82.16; H, 11.93. Found: C, 82.00; H, 11.92. MALDI TOF: m/z 563.418 ($[\text{M}+\text{Na}]^+$, calcd 563.480), 579.375 ($[\text{M}+\text{K}]^+$, calcd 579.454). HRMS (ESI-TOF): calcd for $\text{C}_{37}\text{H}_{64}\text{O}_2\text{Na}$ $[\text{M}+\text{Na}]^+$ 563.4804, found 563.4709.

Figures for spectrum of the compounds 25–27, 29–31, 33–35, 37–39

Figure S1. ^{13}C NMR Spectrum of compound **25** (125 MHz, CDCl_3)




Figure S2. ^1H NMR Spectrum of compound **25** (500 MHz, CDCl_3)




Figure S3. ¹³C NMR Spectrum of compound **26** (125 MHz, CDCl₃)




Figure S4. ¹H NMR Spectrum of compound 26 (500 MHz, CDCl₃)




Figure S5. ^{13}C NMR Spectrum of compound 27 (125 MHz, CDCl_3)




Figure S6. ^1H NMR Spectrum of compound 27 (500 MHz, CDCl_3)




Figure S7. ^{13}C NMR Spectrum of compound 29 (100 MHz, CDCl_3)




Figure S8. ^1H NMR Spectrum of compound **29** (400 MHz, CDCl_3)




Figure S9. ¹³C NMR Spectrum of compound **30** (100 MHz, CDCl₃)




Figure S10. ^1H NMR Spectrum of compound **30** (400 MHz, CDCl_3)




Figure S11. ¹³C NMR Spectrum of compound 31 (100 MHz, CDCl₃)




Figure S12. ^1H NMR Spectrum of compound **31** (400 MHz, CDCl_3)




Figure S13. ¹³C NMR Spectrum of compound 33 (100 MHz, CDCl₃)




Figure S14. ^1H NMR Spectrum of compound 33 (400 MHz, CDCl_3)




Figure S15. ^{13}C NMR Spectrum of compound 34 (100 MHz, CDCl_3)




Figure S16. ¹H NMR Spectrum of compound 34 (400 MHz, CDCl₃)




Figure S17. ^{13}C NMR Spectrum of compound 35 (100 MHz, CDCl_3)




Figure S18. ¹H NMR Spectrum of compound **35** (400 MHz, CDCl₃)




Figure S19. ¹³C NMR Spectrum of compound 37 (125 MHz, CDCl₃)




Figure S20. ¹H NMR Spectrum of compound 37 (500 MHz, CDCl₃)




Figure S21. ¹³C NMR Spectrum of compound **38** (100 MHz, CDCl₃)




Figure S22. ¹H NMR Spectrum of compound **38** (400 MHz, CDCl₃)




Figure S23. ¹³C NMR Spectrum of compound **39** (125 MHz, CDCl₃)




Figure S24. ¹H NMR Spectrum of compound 39 (500 MHz, CDCl₃)




Figure S25. ^{13}C NMR Spectrum of compound 2 (Chatenaytrienin-2) (100 MHz, CDCl_3)




Figure S26. ¹H NMR Spectrum of compound 2 (Chatenaytrienin-2) (400 MHz, CDCl₃)




Figure S27. ¹³C NMR Spectrum of compound 3 (Chatenaytrienin-3) (100 MHz, CDCl₃)




Figure S28. ¹H NMR Spectrum of compound 3 (Chatenaytrienin-3) (400 MHz, CDCl₃)




Figure S29. ¹³C NMR Spectrum of compound 4 (Chatenaytrienin-4) (100 MHz, CDCl₃)







Figure S30. ¹H NMR Spectrum of compound 4 (Chatenaytrienin-4) (400 MHz, CDCl₃)




Live untreated cells



Chatenaytrienin-4



Chatenaytrienin-3








Table S1 with 95% confidence intervals are provided in parentheses

| | Control cells | 1 | 2 | 3 | 4 | Staurosporin |
|-------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| Mitochondria live | 98.82 (97.77 - 99.11) | 0.91 (0.85 - 0.99) | 12.45 (11.99 - 13.95) | 33.38 (31.44 - 34.96) | 43.47 (42.26 - 44.15) | 64.33 (62.75 - 65.55) |
| Mitochondria dead | 0.96 (0.90 - 0.98) | 83.55 (80.12 - 84.44) | 79.00 (76.57 - 80.01) | 49.30 (48.09 - 50.98) | 54.52 (52.64 - 55.16) | 33.04 (32.35 - 35.35) |
| Necrosis | 0 (0.0 - 0.01) | 15.11 (14.13 - 16.15) | 8.44 (7.99 - 9.04) | 17.01 (16.11 - 18.12) | 1.88 (0.99 - 2.01) | 2.48 (1.15 - 2.99) |
| Live | 95.87 | 35.08 | 70.97 | 22.68 | 41.50 | 19.84 |

| | (93.46 – 97.33) | (34.07 – 36.87) | (69.84 – 71.14) | (20.17 – 23.23) | (39.74 – 42.02) | (18.17 – 20.06) |
|-----------------|-----------------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| Early apoptosis | 0 (0.0 – 0.02) | 20.17 (19.19 – 21.20) | 1.86 (0.99 – 2.06) | 18.88 (17.05 – 19.96) | 48.96 (47.47 – 49.11) | 0.27 (0.25 – 0.29) |
| Late apoptosis | 4.13 (3.99 – 4.38) | 44.05 (42.32 – 45.16) | 19.97 (18.88 – 20.08) | 57.86 (55.77 – 58.85) | 8.26 (7.16 – 9.02) | 66.44 (64.12 – 67.85) |

Figure S31. Detection of changes in the mitochondrial membrane potential ($\Delta\Psi$) in Jurkat cells treated with chatenaytrienins-1, -2, -3 and -4 (1–4), taken at a concentration of IC50: (A) control sample containing living cells; (B) chatenaytrienin-4 (4); (C) chatenaytrienin-3 (3); (D) chatenaytrienin-2 (2); (E) chatenaytrienin-1 (1); (G) staurosporine. The cells were stained with MitoSense Red, Annexin V – with CF488A and 7-AAD (FlowCollect® MitoDamage Kit). Incubation time was 4 hours. Cytofluorometric analysis covered the data of three independent experiments. 95% confidence intervals are provided in parentheses in Table S1.









Table S2 with 95% confidence intervals are provided in parentheses

| | Control | 1 | 2 | 3 | 4 | Antimycin |
|-----------------|--------------------------|---------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| Live cells | 99.51 (97.45 - 99.99) | 14.26 (13.66 - 16.17) | 29.76 (26.11 - 30.01) | 41.68 (40.15 - 43.06) | 9.9 (8.16 - 10.17) | 12.65 (11.15 - 13.36) |
| Apoptosis cells | 0.46 (0.56-0.51) | 75.19 (73. 78 - 76.67) | 57.85 (56.65 - 58.11) | 55.33 (54.54 - 56.84) | 63.94 (60.14 - 65.12) | 79.81 (77.11 - 80.01) |
| Stress cells | 0 (0 - 0.01) | 0.02 (0.0 - 0.03) | 0.53 (0.46 - 0.570) | 0.04 (0.02 - 0.05) | 0.09 (0.07 - 0.10) | 0 (0.0 - 0.01) |

| | | | | | | |
|------------------------|-------------------|------------------------|--------------------------|-----------------------|--------------------------|-----------------------|
| Apoptosis+Stress cells | 0 (0.0 – 0.02) | 10.53 (9.88 -10.87) | 11.86 (10.11 – 13.06) | 2.95 (1.99 – 3.07) | 26.08 (25.12 – 27.43) | 7.54 (7.01 – 7.98) |
|------------------------|-------------------|------------------------|--------------------------|-----------------------|--------------------------|-----------------------|

Figure S32. Detection of oxidative stress and early apoptosis events in Jurkat cells treated with chatenaytrienins-1, -2, -3 and -4 (**1–4**) taken at a concentration IC50: (A) control sample; (B) chatenaytrienin-1 (**1**); (C) chatenaytrienin-2 (**2**); (D) chatenaytrienin-3 (**3**); (E) chatenaytrienin-4 (**4**); (F) antimycin (100μM). MitoSOX Red and Annexin V stain, CF647 (FlowCollect™ MitoStress Kit). Incubation time was 4 hours. Cytofluorometric analysis involved the data of three independent experiments. 95% confidence intervals are provided in parentheses in Table S2.






Table S3 with 95% confidence intervals are provided in parentheses

| | Control | 1 | 2 | 3 | 4 |
|-------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
| G1 | 49.34 (44.15 - 50.11) | 43.37 (41.55 - 44.43) | 41.12 (39.39 - 42.11) | 46.95 (44.54 - 47.77) | 43.39 (42.34 - 45.15) |
| S | 36.9 (35.16 - 37.18) | 42.2 (39.18 - 43.43) | 47.07 (45.65 - 48.19) | 40.37 (39.90 - 41.45) | 41.34 (39.45 - 43.01) |
| G2/M | 13.64 (11.43 - 14.23) | 5.37 (4.32 - 6.74) | 3.42 (2.23 - 3.98) | 8.95 (7.15 - 9.20) | 5.95 (4.15 - 6.18) |
| subG0 | 0.41 (0.46 - 0.49) | 0.78 (0.73 - 0.79) | 0.5 (0.35 - 0.56) | 1.02 (0.99 - 1.15) | 0.53 (0.45 - 0.65) |

Figure S33. Histograms of cytofluorometric analysis of cell cycle phases in Jurkat cells under the influence of the studied acetogenins. The cells treated with chatenaytrienins-1. -2. -3 and -4 (1–4) at IC50: (1) control; (2) chatenaytrienin-1 (1); (3) chatenaytrienin-2 (2); (4) chatenaytrienin-3 (3); (5) chatenaytrienin-4 (4). Guava® Cell Cycle Reagent stain. The time of incubation of compounds with cells was 48 hours. All results of cytofluorometric analysis were obtained from at least three independent experiments. 95% confidence intervals are provided in parentheses in Table S3.

Data from MILLIPLEX® 7-plex Early Apoptosis Magnetic Bead Kit and MILLIPLEX® MAP 7-plex DNA Damage/Genotoxicity Magnetic Bead Kit used in Jurkat cells upon 6-h and 12-h exposure to test substances.

| | Chk2 | | Chk1 | | MDM2 | | H2A.X | | p21 | | ATR | | BAD | | Cas8 | | Bcl-2 | | Cas9 | | JNK | | p53 | |
|-------------------|------------------------------------|------------------------------------|---------------------------------------|---------------------------------------|------------------------------------|------------------------------------|--------------------------------------|-------------------------------------|---------------------------------------|---------------------------------------|---------------------------------------|-----------------------------------|------------------------------------|------------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|----------------------------------|--|-------------------------------------|-----------------------------------|--------------------------------------|
| | 6 h | 12 h | 6h | 12h | 6h | 12h | 6h | 12h | 6h | 12h | 6h | 12h | 6h | 12h | 6h | 12h | 6h | 12h | 6h | 12h | 6h | 12h | 6h | 12h |
| Chatenaytrienin-1 | 19.54 (18.30- -21.23) | 85.52 (83.88- 87.93) | 9.53 (8.15- 10.25) | 89.44 (88.95- 90.11) | 15.55 (13.28- 18.75) | 231.88 (230.1- 233.18) | 1724.65 (1699.9- 1768.87) | 2004.58 (1998.1- 2015.44) | 15.58 (13.4- 4- 5- 17.80) | 79.15 (76.1- 3- 6- 80.33) | 51.96 (49.9- 9- 4- 54.86) | 145.20 (142.3- 147.18) | 18.94 (149.1- 153.28) | 151.49 (149.1- 159.99) | 8.65 (6.87- 4- 85.74) | 83.35 (81.1- 2- 5.55) | 4.51 (3.33- 2- 58.12) | 56.78 (53.7- 6- 3.45) | 2.75 (1.05- - 82.54) | 80.33 (77.6- 5- 225.76) | 218.66 (201.4- 3- 3-578- 44) | 575.76 (570.4- 678.30) | 670.11 (666.23- - 83.94) | 80.94 (78.25- - -) |
| Muricadienin | 4.85 (5.11- 6.18) | 79.45 (78.54- 79.37) | 4.53 (3.58 - 5.86) | 80.55 (79.14- 82.13) | 31.76 (29.87- 34.77) | 217.56 (216.1- 2-2678.32 | 2397.45 (2254.4- 6- 222.16) | 2561.54 (2558.1- 73.22) | 1.5 (1.05- 2.56) | 71.59 (68.4- 3- 73.22) | 58.33 (55.4- 3- 60.23) | 140.99 (138.4- 142.20) | 13.56 (11.64- 6- 15.65) | 152.28 (149.3- 4- 155.18) | 10.5 (9.99- 12.11) | 87.16 (84.9- 7- 89.65) | 1.5 (1.02- 2.18) | 53.99 (49.9- 9- 54.89) | 4.25 (75.4- 3- 81.15) | 79.85 (75.4- 5- 330.65) | 586.90 (580.9- 9- 590.35) | 328.98 (323.3- 5- -) | 586.31 (580.77- - -) | 697.99 (690.32- - 699.86) |
| Control | 735.11 (720.3- 3- 740.28) | 703.48 (701.5- 3- 705.37) | 1316.35 (1333.7- 6- 1340.29) | 1206.57 (1193.6- 6- 1230.59) | 168.61 (163.4- 5- 170.38) | 166.61 (162.4- 0- 168.35) | 118.76 (115.89- - 120.96) | 112.35 (110.43- 9- 115.87) | 65.87 (59.9- 2- 68.55) | 59.44 (57.3- 5- 61.30) | 63.86 (60.2- 5- 66.75) | 61.58 (59.32- 8- 840.25) | 801.45 (798.6- 8- 866.45) | 864.76 (860.8- 8- 85.15) | 80.67 (79.1- 6- 88.25) | 86.24 (83.7- 7- 68.87) | 65.18 (62.1- 2- 55.98) | 54.18 (52.1- 1- 72.38) | 80.99 (79.0- 1- 77.34) | 75.76 (72.7- 8- 538.59) | 520.18 (505.3- 7- 533.57) | 530.18 (527.6- 7- 1044.36) | 1030.18 (1006.8- 0- -) | 1099.5 (1078.2- 4- 1112.65) |

Data from MILLIPLEX Multi-Pathway Magnetic Bead 9-Plex - Cell Signaling Multiplex Assay used in Jurkat cells upon 4-h exposure to test substances.

| | CREB | JNK | NFkB | p38 | ERK1/2 | Akt | p70S6K | STAT3 | STAT5 |
|-------------------|--------------------------------|--------------------------------|-----------------------------|-----------------------------------|--------------------------------|-----------------------------------|--------------------------------|--------------------------------|-----------------------------|
| Chatenaytrienin-1 | 244.87 (230.13- 250.67) | 225.15 (220.14 – 228.96) | 73.54 (70.87 – 76.22) | 763.84 (758.20 – 773.12) | 183.59 (179.25 – 187.54) | 749.88 (745.55 – 756.16) | 149.85 (145.15 – 152.65) | 123.65 (120.14 – 126.88) | 93.59 (89.99 – 95.14) |
| Muricadienin | 281.15 (278.46- 285.97) | 301.97 (299.14 – 305.45) | 62.96 (60.15 – 67.89) | 1083.01 (1006.33 – 115.12) | 158.23 (150.11 - 161.20) | 965.83 (950.34 – 970.57) | 122.85 (119.74 – 126.74) | 100.15 (98.15 – 105.88) | 85.85 (80.20 - 88.15) |
| Control | 544.74 (537.19 – 559.63) | 104.34 (100.54 – 108.82) | 70.10 (68.64 – 74.11) | 2511.11 (2499.45 – 2567.17) | 294.10 (290.76 – 298.16) | 4269.13 (4250.45 - 4286.66) | 128.38 (120.66 – 130.11) | 102.44 (100.35 – 106.47) | 85.14 (80.01 - 89.00) |